

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# Hutchison Whampoa Limited

*(incorporated in Hong Kong with limited liability)*  
**(Stock Code: 13)**

## OVERSEAS REGULATORY ANNOUNCEMENT

Please refer to the attached announcement of Hutchison China MediTech Limited, which is listed on the Alternative Investment Market operated by the London Stock Exchange and a 71.6% owned subsidiary of Hutchison Whampoa Limited.

As at the date of this announcement, the Directors of the Company are:

**Executive Directors:**

Mr LI Ka-shing (*Chairman*)  
Mr LI Tzar Kuoi, Victor (*Deputy Chairman*)  
Mr FOK Kin-ning, Canning  
Mrs CHOW WOO Mo Fong, Susan  
Mr Frank John SIXT  
Mr LAI Kai Ming, Dominic  
Mr KAM Hing Lam

**Non-executive Directors:**

Mr George Colin MAGNUS  
Mr William SHURNIAK

**Independent Non-executive Directors:**

The Hon Sir Michael David KADOORIE  
Mr Holger KLUGE  
Mrs Margaret LEUNG KO May Yee  
Mr William Elkin MOCATTA  
*(Alternate to The Hon Sir Michael  
David Kadoorie)*  
Mr WONG Chung Hin

Hong Kong, 29 July 2009



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**Patient Enrolment Completed Ahead of Schedule for the Global Phase IIb  
Ulcerative Colitis Trial of HMPL-004**

**London: Wednesday, 29 July 2009:** Hutchison MediPharma Limited (“Hutchison MediPharma”), the wholly-owned drug R&D subsidiary of Chi-Med, today announces the completion well ahead of schedule of patient enrolment into a Phase IIb trial of HMPL-004 in patients with mild-to-moderate Ulcerative Colitis (“UC”), a form of inflammatory bowel disease (IBD). Results from this trial are now expected to be available in the fourth quarter of this year.

Today’s announcement follows both the positive results for HMPL-004’s Phase II proof-of-concept study conducted in UC patients in China, announced in July 2007, and the recent encouraging results of HMPL-004’s Phase II trial in Crohn’s Disease in the US and Ukraine, announced on 13 July this year.

The global Phase IIb UC clinical trial has been designed to further test the drug candidate’s efficacy and safety profiles in a broad patient population and different dose levels in preparation for the Phase III registration trials. The patient recruitment of the global UC trial involved some 50 clinical study centres worldwide including sites in North America and Europe.

The global phase IIb UC trial is a multi-center, randomized, double-blind and placebo-controlled clinical study of 210 patients with active mild-to-moderate UC. In the trial, the patients are enrolled and randomized into one of the HMPL-004 treatment arms, 1200mg/daily or 1800mg/daily, or the placebo arm. The primary trial objective is the efficacy of HMPL-004 in clinical response as compared with the placebo after 8 weeks treatment. The clinical response is defined by quantitative symptom reduction thresholds using the standard Mayo score, along with the rectal bleeding score from the colonoscopic examination. Secondary end points of the trial involve the clinical remission, mucosal healing, and the dose response trend of the two treatment arms. Safety evaluations will be made throughout the trial period.

HMPL-004 is an orally administered, proprietary botanical product that acts on multiple targets in the pathogenesis of inflammation. It is extracted from a Chinese herb that has extensive history of use in China and South East Asia against respiratory infections and inflammation.

Hutchison MediPharma's extensive preclinical work has shown that HMPL-004 acts on multiple cellular targets in the inflammatory signal transduction pathways resulting in suppressed inflammation cytokine expression including TNF-alpha, IL-1 beta and IL-6. HMPL-004 was demonstrated to inhibit TNF-alpha and IL-1 beta production in cell-based assays and is also able to inhibit NF-kB activation. The novel mechanism of action of HMPL-004, compared to current conventional therapies, including Mesalazine, allows it to access a unique IBD patient population.

## **Ends**

### **Enquiries**

#### **Chi-Med**

Christian Hogg, CEO

Telephone: +852 2121 8200

#### **Citigate Dewe Rogerson**

Anthony Carlisle

David Dible

Telephone: +44 (0) 20 7638 9571

+44 (0) 7973 611 888

+44 (0) 7967 566 919

### **About Chi-Med**

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients.

Hutchison MediPharma is Chi-Med's wholly-owned drug R&D subsidiary and has a team of around 200 scientists and staff focusing on discovery and development of botanical drugs, semi-synthetic natural product drugs, and synthetic single chemical entity drugs. Hutchison MediPharma has a pipeline of single new chemical entity discovery projects in both the auto-immune/inflammatory disease and oncology therapeutic areas.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.